Real-World Clinical Outcomes of Ujvira® (Trastuzumab Emtansine Biosimilar) in HER2-Positive Breast Cancer: A Retrospective Observational Study in Indian Patients

• Naveen Karuvandan

  D.M. Medical Oncology, Dr G Viswanathan CBCC Cancer Center, Trichy, Tamil Nadu, India

• Pradeep Ventrapati

  D.M. Medical Oncology, Apollo Hospitals, Visakhapatnam, Andhra Pradesh, India

Background: HER2-positive breast cancer is an aggressive subtype requiring targeted therapies. Trastuzumabemtansine has shown efficacy in clinical trials but remains costly, limiting accessibility in low-resource settings. Ujvira^®, a biosimilar of T-DM1, offers a more affordable alternative. This study evaluates its real-world efficacy and safety in Indian patients.

Methods: This is a retrospective analysis of HER2-positive breast cancer patients treated with Ujvira® between January 2022 and December 2023 at a tertiary care center in India. Primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), safety and clinical response per RECIST v1.1. Kaplan-Meier analysis was used for survival estimates; comparisons across lines of therapy were assessed using the log-rank test.

Results: The study included 23 patients (median age 51 years, range 35–72), with 74% having an ECOG performance status of 0–1. T-DM1 biosimilar was administered in a palliative setting to 20 patients and as adjuvant therapy to 3 patients. Among the palliative group, 45% had brain metastases at baseline, and treatment was given as second-line in 45%, third-line in 40%, and fourth-line or later in 15% of cases. Overall, 50% achieved a partial response, 35% had stable disease, and 15% showed disease progression. At a median follow-up of 15 months, 30% remained on treatment, 65% had progressed, and one patient was lost to follow-up. The median PFS was 9.6 months, and the median OS was 14 months. In the adjuvant setting, 2 of 3 patients completed 14 cycles, while one progressed with brain metastases after 9 cycles. The most common adverse events were thrombocytopenia, anemia, and transaminitis, with grade 3 events occurring in 26% and grade 4 events in 4% of patients.

Conclusion: Ujvira® showed efficacy comparable to innovator T-DM1 in terms of PFS, supporting its role in HER2-positive breast cancer management. However, shorter OS may reflect high brain metastases rates and limited access to post-progression therapies. The study’s retrospective design, small sample size, and selection bias limit generalizability. Larger prospective studies are needed to validate findings.

[1] Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.

[2] Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 2009; 14: 320-368.

[3] Michel LL, Bermejo JL, Gondos A, Marmé F, Schneeweiss A. T-DM1 as a New Treatment Option for Patients with Metastatic HER2-positive Breast Cancer in Clinical Practice. Anticancer Res 2015; 35(9): 5085-5090.

[4] Watanuki R, Shimomura A, Yazaki S, et al. Survival outcomes in patients with human epidermal growth factor receptor 2 positive metastatic breast cancer administered a therapy following trastuzumabemtansine treatment. Medicine (United States) 2020; 99(38): E22331.

[5] Recondo G, de la Vega M, Galanternik F, Díaz-Cantón E, Leone BA, Leone JP. Novel approaches to target HER2-positive breast cancer: trastuzumabemtansine. Cancer Manag Res 2016; 8: 57-65.

[6] Diéras V, et al. Trastuzumabemtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. The Lancet Oncology 2017; 18(6): 732-742.

[7] Krop IE, et al. Trastuzumabemtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. The Lancet Oncology 2017; 18(6): 743-754.

[8] Hurvitz SA, et al. Trastuzumabderuxtecan versus trastuzumabemtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. The Lancet 2022; 401(10371): 105-117.

[9] Curigliano G, et al. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis. Annals of Oncology 2021; 33(3): 321-329.

[10] Geyer CE Jr., et al. Survival with TrastuzumabEmtansine in Residual HER2-Positive Breast Cancer. N Engl J Med 2025; 392: 249-257.

[11] Diéras V, Harbeck N, Budd GT, et al. Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: An Integrated Safety Analysis. Journal of Clinical Oncology 2014; 32(25): 2750-2757.

[12] Yan H, Yu K, Zhang K, Liu L, Li Y. Efficacy and safety of trastuzumabemtansine (T-DM1) in the treatment of HER2-positive metastatic breast cancer (MBC): a meta-analysis of randomized controlled trial. Oncotarget 2017; 8(60): 102458-102467.

[13] Perachino M, et al. Adverse events and impact on quality of life of antibody-drug conjugates in the treatment of metastatic breast cancer: A systematic review and meta-analysis. European Journal of Clinical Investigation.

[14] Hardy-Werbin M, Quiroga V, Cirauqui B, et al. Real-world data on T-DM1 efficacy – results of a single-center retrospective study of HER2-positive breast cancer patients. Sci Rep 2019; 9(1).

• PDF

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.